OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Not yet recruiting · NCT07739017 · Registry updated 2026-07-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 1 | 2026-07-31 | NCT07739017 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Curtana Pharmaceuticals, Inc. | 1 |
| Olivia Newton-John Cancer Research Institute | 8 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Health | Heidelberg | Australia | 70 |
| Royal Brisbane and Women's Hospital | Herston | Australia | 12 |